Zevra Therapeutics, Inc. ZVRA Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $124.22M+49.2% | $83.23M+136% | $35.33M+1,236% | $2.64M+103% | -$91.99M+12.8% | ||
| $2.77M-31.6% | $4.05M-24.1% | $5.34M-18.7% | $6.57M+1.4% | $6.48M+1.4% | ||
| $12.62M-0.1% | $12.63M+2.2% | $12.37M-21.4% | $15.73M-1.1% | $15.9M+6.7% | ||
| —— | —— | —— | —— | $0— | ||
| $1.29M-1.5% | $1.31M-76.3% | $5.5M-6.6% | $5.88M-9.4% | $6.49M-26.8% | ||
| -$9.26M+42.1% | -$16M— | —— | —— | —— | ||
| -$2.22M-392% | -$451K-113% | $3.34M+690% | -$566K-71.5% | -$330K— | ||
| -$1.3M-12.4% | -$1.16M-117% | $6.69M+168% | $2.49M+47.3% | $1.69M+103% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $414K-25.0% | ||
| —— | —— | —— | —— | —— | ||
| -$608K+9.9% | -$675K+13.1% | -$777K-295% | $398K+158% | -$686K-9.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$46.21M+25.1% | -$61.72M+11.4% | ||
| $802K-7.4% | $866K0.0% | $866K+178% | $312K+215% | $99K— | ||
| $360.92M+16.4% | $309.99M+17.4% | $263.98M+32.8% | $198.74M+310% | $48.52M+17.9% | ||
| $254.47M+42.6% | $178.5M+95.7% | $91.2M+124% | $40.71M+44.3% | $28.21M+12.8% | ||
| —— | $0-100% | $1.5M-50.0% | $3M-33.3% | $4.5M-25.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$14.35M+45.7% | -$26.41M-19.2% | ||
| $60.09M— | $0— | —— | —— | —— | ||
| $752K— | $0— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$42.35M-451% | $12.06M+17.0% | $10.31M-85.0% | $68.55M-16.9% | $82.5M+0.5% | ||
| —— | —— | $1.02M+119% | $466K+267% | $127K-72.0% | ||
| $58.26M+104% | $28.62M+7,055% | $400K-95.3% | $8.45M+253% | -$5.51M+40.5% | ||
| $5.39M+1.2% | $5.33M-4.6% | $5.59M-2.9% | $5.75M-10.5% | $6.43M+22.2% | ||
| $3.45M+10.2% | $3.13M-1.0% | $3.16M+62.1% | $1.95M+63.2% | $1.2M+34.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $64K+143% | -$149K-303% | -$37K-1,133% | -$3K+50.0% | -$6K-133% | ||
| —— | —— | —— | —— | —— | ||
| $1.73M+179% | -$2.18M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $18.76M+13.3% | $16.56M+7.7% | ||
| —— | —— | —— | —— | —— | ||
| -$608K+9.9% | -$675K+13.1% | -$777K-295% | $398K+158% | -$686K-9.6% | ||
| —— | —— | —— | —— | —— | ||
| -$1.3M-12.4% | -$1.16M-117% | $6.69M+168% | $2.49M+47.3% | $1.69M+103% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $5.12M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $12.19M+4.1% | $11.7M-4.1% | $12.2M-14.1% | $14.2M+149% | $5.7M-0.8% | ||
| —— | —— | —— | —— | $414K-25.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | $0-100% | $1.5M-50.0% | $3M-33.3% | $4.5M-25.0% | ||
| $360.92M+16.4% | $309.99M+39.1% | $222.82M+11.9% | $199.07M+308% | $48.85M+17.7% | ||
| $254.47M+42.6% | $178.5M+95.7% | $91.2M+124% | $40.71M+44.3% | $28.21M+12.8% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $60.09M— | $0— | —— | —— | —— | ||
| —— | —— | $1.02M+119% | $466K+267% | $127K-72.0% | ||
| -$608K+9.9% | -$675K+13.1% | -$777K-295% | $398K+158% | -$686K-9.6% | ||
| —— | —— | —— | —— | $1.53M+266% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$46.53M+24.7% | -$61.82M+11.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Zevra Therapeutics, Inc. generate?
- Zevra Therapeutics, Inc. (ZVRA) generated -$21.9M in operating cash flow over the trailing twelve months.
- What is Zevra Therapeutics, Inc.'s free cash flow?
- After $802.0K of capital expenditures, Zevra Therapeutics, Inc.'s free cash flow was -$22.3M over the trailing twelve months, up 68.0% year over year.
- Where does Zevra Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Zevra Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
